De Lepeleire I - Search Results

1

The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.

Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E. Dallob A, et al. Among authors: de lepeleire i, de hoon jn. Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 28. Platelets. 2011. PMID: 21526889 Clinical Trial.

2

Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.

Depré M, Margolskee DJ, Hsieh JY, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, De Schepper PJ. Depré M, et al. Among authors: de lepeleire i, de schepper pj. Eur J Clin Pharmacol. 1992;43(4):427-30. doi: 10.1007/BF02220621. Eur J Clin Pharmacol. 1992. PMID: 1451725 Clinical Trial.

3

Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man.

Arnout J, van Hecken A, De Lepeleire I, Miyamoto Y, Holmes I, De Schepper P, Vermylen J. Arnout J, et al. Among authors: de schepper p, de lepeleire i. Br J Clin Pharmacol. 1988 Apr;25(4):445-51. doi: 10.1111/j.1365-2125.1988.tb03328.x. Br J Clin Pharmacol. 1988. PMID: 3289599 Free PMC article. Clinical Trial.

4

Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men.

Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J. Barrett JS, et al. Among authors: de lepeleire i. Clin Pharmacol Ther. 1994 Oct;56(4):377-88. doi: 10.1038/clpt.1994.152. Clin Pharmacol Ther. 1994. PMID: 7955799 Clinical Trial.

5

Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.

Depré M, Friedman B, Van Hecken A, de Lepeleire I, Tanaka W, Dallob A, Shingo S, Porras A, Lin C, de Schepper PJ. Depré M, et al. Among authors: de lepeleire i, de schepper pj. Clin Pharmacol Ther. 1994 Jul;56(1):22-30. doi: 10.1038/clpt.1994.96. Clin Pharmacol Ther. 1994. PMID: 8033491 Clinical Trial.

6

Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects.

Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, Ng J, De Schepper PJ. Van Hecken A, et al. Among authors: de lepeleire i, de schepper pj. Eur J Clin Pharmacol. 1994;46(2):123-6. doi: 10.1007/BF00199874. Eur J Clin Pharmacol. 1994. PMID: 8039530

7

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

Schwartz JI, Van Hecken A, De Schepper PJ, De Lepeleire I, Lasseter KC, Shamblen EC, Winchell GA, Constanzer ML, Chavez CM, Wang DZ, Ebel DL, Justice SJ, Gertz BJ. Schwartz JI, et al. Among authors: de lepeleire i, de schepper pj. J Clin Endocrinol Metab. 1996 Aug;81(8):2942-7. doi: 10.1210/jcem.81.8.8768856. J Clin Endocrinol Metab. 1996. PMID: 8768856 Clinical Trial.

8

Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.

Depré M, Van Hecken A, Verbesselt R, De Lepeleire I, Schwartz J, Porras A, Larson P, Lin C, De Schepper PJ. Depré M, et al. Among authors: de lepeleire i, de schepper pj. Int J Clin Pharmacol Res. 1998;18(2):53-61. Int J Clin Pharmacol Res. 1998. PMID: 9675622 Clinical Trial.

9

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.

Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ. Ehrich EW, et al. Among authors: de schepper p, de lepeleire i. Clin Pharmacol Ther. 1999 Mar;65(3):336-47. doi: 10.1016/S0009-9236(99)70113-X. Clin Pharmacol Ther. 1999. PMID: 10096266 Clinical Trial.

10

Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers.

Depré M, Van Hecken A, Verbesselt R, Wynants K, De Lepeleire I, Freeman A, Holland S, Shahane A, Gertz B, De Schepper PJ. Depré M, et al. Among authors: de lepeleire i, de schepper pj. J Clin Pharmacol. 1999 Sep;39(9):941-4. doi: 10.1177/00912709922008579. J Clin Pharmacol. 1999. PMID: 10471986 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page